https://doi.org/10.4081/ecj.2023.11349
Selective serotonin reuptake inhibitors related bleeding risk: case report and review of literature
Submitted: 1 April 2023
Accepted: 27 July 2023
Published: 8 August 2023
Accepted: 27 July 2023
Abstract Views: 970
PDF: 315
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Gastrointestinal bleedings are relevant side effects in patients during anticoagulant therapy for atrial fibrillation. Direct oral anticoagulants (DOACs) are less correlated with major bleeding events than vitamin K antagonists (VKAs), but concerns are present about the relative risk of gastrointestinal bleeding. Here we report the case of a patient with atrial fibrillation and dementia on DOAC treatment who developed a SSRI-associated thrombocytopenia with subsequent life-threatening bleeding. Physicians should be aware of the possible correlation between SSRI-induced thrombocytopenia and concomitant use of anticoagulant and/or antiplatelet drugs, thus preventing life-threatening bleedings.
Alam SM, Qasswal M, Ahsan MJ, et al. Selective serotonin reuptake inhibitors increase risk of upper gastrointestinal bleeding when used with NSAIDs: a systemic review and meta-analysis. Sci Rep 2022;12:14452.
DOI: https://doi.org/10.1038/s41598-022-18654-2
Bakker S, Burggraaf JLI, Kruip M, et al. Selective Serotonin Reuptake Inhibitor Use and Risk of Major Bleeding during Treatment with Vitamin K Antagonists: Results of A Cohort Study. Thromb Haemost 2023;123:245-254.
DOI: https://doi.org/10.1055/a-1957-6305
Edinoff AN, Raveendran K, Colon MA, et al. Selective Serotonin Reuptake Inhibitors and Associated Bleeding Risks: A Narrative and Clinical Review. Health Psychol Res 2022;10:39580.
DOI: https://doi.org/10.52965/001c.39580
Garg PK, O'Neal WT, Diez-Roux AV, et al. Negative Affect and Risk of Atrial Fibrillation: MESA. J Am Heart Assoc 2019;8:e010603.
DOI: https://doi.org/10.1161/JAHA.118.010603
Fu Y, Feng S, Xu Y, et al. Association of Depression, Antidepressants With Atrial Fibrillation Risk: A Systemic Review and Meta-Analysis. Front Cardiovasc Med 2022;9:897622.
DOI: https://doi.org/10.3389/fcvm.2022.897622
Hallbäck I, Hägg S, Eriksson AC, Whiss PA. In vitro effects of serotonin and noradrenaline reuptake inhibitors on human platelet adhesion and coagulation. Pharmacol Rep 2012;64:979-83.
DOI: https://doi.org/10.1016/S1734-1140(12)70894-0
Andersohn F, Konzen C, Bronder E, et al. Citalopram-induced bleeding due to severe thrombocytopenia. Psychosomatics 2009;50:297-298.
DOI: https://doi.org/10.1176/appi.psy.50.3.297
McFarland D, Merchant D, Khandai A, et al. Selective Serotonin Reuptake Inhibitor (SSRI) Bleeding Risk: Considerations for the Consult-Liaison Psychiatrist. Curr Psychiatry Rep 2023;25:113-124.
DOI: https://doi.org/10.1007/s11920-023-01411-1
Ataoglu A, Canan F. Mean platelet volume in patients with major depression: effect of escitalopram treatment. J Clin Psychopharmacol 2009;29:368-71.
DOI: https://doi.org/10.1097/JCP.0b013e3181abdfd7
Song HR, Jung YE, Wang HR, et al. Platelet count alterations associated with escitalopram, venlafaxine and bupropion in depressive patients. Psychiatry Clin Neurosci 2012;66:457-59.
DOI: https://doi.org/10.1111/j.1440-1819.2012.02355.x
Lopez-Vilchez I, Jerez-Dolz D, Diaz-Ricart M, et al. Escitalopram Impairs Thrombin-Induced Platelet Response, Cytoskeletal Assembly and Activation of Associated Signalling Pathways. Thromb Haemost 2017;117:2312-2321.
DOI: https://doi.org/10.1160/TH17-04-0288
Atar D, Malinin A, Pokov A, et al. Antiplatelet properties of escitalopram in patients with the metabolic syndrome: a dose-ranging in vitro study. Neuropsychopharmacology 2007;32:2369-2374.
DOI: https://doi.org/10.1038/sj.npp.1301355
Tseng YL, Chiang ML, Lane HY, et al. Selective serotonin reuptake inhibitors reduce P2Y12 receptor-mediated amplification of platelet aggregation. Thrombosis Res 2013;131:325-332.
DOI: https://doi.org/10.1016/j.thromres.2013.02.007
Canan F, Ataoglu A. The effect of escitalopram on platelet activity. Thrombosis Res 2011;127:57.
DOI: https://doi.org/10.1016/j.thromres.2010.07.017
Hirsh-Rokach B, Spectre G, Shai E, et al. Differential impact of selective serotonin reuptake inhibitors on platelet response to clopidogrel: a randomized, double-blind, crossover trial. Pharmacotherapy 2015;35:140-147.
DOI: https://doi.org/10.1002/phar.1542
Narayana PV, Satpathy PK, Gowda SB, Addepalli S. Budd-Chiari Syndrome as an Initial Presentation of Antiphospholipid Syndrome in a Male. J Clin Diagnostic Res 2022;16:OD10-OD12.
DOI: https://doi.org/10.7860/JCDR/2022/54902.16408
Maurer-Spurej E, Pittendreigh C, Solomons K. The influence of selective serotonin reuptake inhibitors on human platelet serotonin. Thrombosis Haemost 2004;91:119-128.
DOI: https://doi.org/10.1160/TH03-05-0330
Van Holten TC, Roest M, Riphagen J, et al. Citalopram is a more potent platelet function inhibitor than paroxetine in a case-control study. J Thromb Haemostasis 2012;10:1177-1179.
DOI: https://doi.org/10.1111/j.1538-7836.2012.04703.x
Roweth HG, Cook AA, Moroi M, et al. Two novel, putative mechanisms of action for citalopram-induced platelet inhibition. Sci Rep 2018;8:16677.
DOI: https://doi.org/10.1038/s41598-018-34389-5
Andrade C, Sandarsh S, Chethan KB, Nagesh KS. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiat 2010;71:1565-1575.
DOI: https://doi.org/10.4088/JCP.09r05786blu
Opatrny L, Delaney JA, Suissa S. Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look. Br J Clin Pharmacol 2008;66:76-81.
DOI: https://doi.org/10.1111/j.1365-2125.2008.03154.x
Haghbin H, Zakirkhodjaev N, Husain FF, et al. Risk of Gastrointestinal Bleeding with Concurrent Use of NSAID and SSRI: A Systematic Review and Network Meta-Analysis. Dig Dis Sci 2023;68:1975-1982.
DOI: https://doi.org/10.1007/s10620-022-07788-y
Lee MT, Park KY, Kim MS, et al. Concomitant Use of NSAIDs or SSRIs with NOACs Requires Monitoring for Bleeding. Yonsei Med J 2020;61:741-749.
DOI: https://doi.org/10.3349/ymj.2020.61.9.741
Wallerstedt SM, Gleerup H, Sundstrom A, et al. Risk of clinically relevant bleeding in warfarin-treated patients--influence of SSRI treatment. Pharmacoepidemiol Drug Safety 2009;18:412-416.
DOI: https://doi.org/10.1002/pds.1737
Quinn GR, Singer DE, Chang Y, et al. Effect of selective serotonin reuptake inhibitors on bleeding risk in patients with atrial fibrillation taking warfarin. Am J Cardiol 2014;114:583-586.
DOI: https://doi.org/10.1016/j.amjcard.2014.05.037
Hrstic I, Kalauz M, Cukovic-Cavka S, et al. Treatment of extensive subacute portal, mesenteric and ileocolic vein thrombosis with recombinant tissue plasminogen activator. Blood Coagul Fibrinolysis 2007;18:581-583.
DOI: https://doi.org/10.1097/MBC.0b013e328285d822
Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V et al: [The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary]. Kardiol Pol 2018;76:1283-1298.
DOI: https://doi.org/10.5603/KP.2018.0180
Brieger D, Amerena J, Attia J, et al. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018. Heart Lung Circ 2018;27:1209-1266.
DOI: https://doi.org/10.1016/j.hlc.2018.06.1043
Bezabhe WM, Bereznicki LR, Radford J, et al. Five-Year Trends in Potential Drug Interactions with Direct-Acting Oral Anticoagulants in Patients with Atrial Fibrillation: An Australian-Wide Study. J Clin Med 2020;9.
DOI: https://doi.org/10.3390/jcm9113568
Forbes HL, Polasek TM. Potential drug-drug interactions with direct oral anticoagulants in elderly hospitalized patients. Ther Adv Drug Saf 2017;8:319-328.
DOI: https://doi.org/10.1177/2042098617719815
Zhang Y, Souverein PC, Gardarsdottir H, et al. Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: A population-based nested case-control study. Br J Clin Pharmacol 2020;86:1150-1164.
DOI: https://doi.org/10.1111/bcp.14227
Quinn GR, Hellkamp AS, Hankey GJ, et al. Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial. J Am Heart Assoc 2018;7:e008755.
DOI: https://doi.org/10.1161/JAHA.118.008755
Ahsberg K, Hoglund P, Kim WH, von Holstein CS. Impact of aspirin, NSAIDs, warfarin, corticosteroids and SSRIs on the site and outcome of non-variceal upper and lower gastrointestinal bleeding. Scand J Gastroenterol 2010;45:1404-1415.
DOI: https://doi.org/10.3109/00365521.2010.510567
Wang Y, Zhang H, Chai F, et al. The effects of escitalopram on myocardial apoptosis and the expression of Bax and Bcl-2 during myocardial ischemia/reperfusion in a model of rats with depression. BMC Psychiatry 2014;14:349.
DOI: https://doi.org/10.1186/s12888-014-0349-x
Jiang W, Velazquez EJ, Kuchibhatla M, et al. Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial. JAMA 2013;309:2139-2149.
DOI: https://doi.org/10.1001/jama.2013.5566
Ziegelstein RC, Meuchel J, Kim TJ, et al. Selective serotonin reuptake inhibitor use by patients with acute coronary syndromes. Am J Med 2007;120:525-530.
DOI: https://doi.org/10.1016/j.amjmed.2006.10.026
Mathews MJ, Mathews EH, Liebenberg L. The mechanisms by which antidepressants may reduce coronary heart disease risk. BMC Cardiovasc Dis 2015;15:82.
DOI: https://doi.org/10.1186/s12872-015-0074-5
Fernandes N, Prada L, Rosa MM, et al. The impact of SSRIs on mortality and cardiovascular events in patients with coronary artery disease and depression: systematic review and meta-analysis. Clin Res Cardiol 2021;110:183-193.
DOI: https://doi.org/10.1007/s00392-020-01697-8
Iasella CJ, Kreider MS, Huang L, et al. Effect of Selective Serotonin Reuptake Inhibitors on Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Retrospective Cohort Study. Clin Drug Investig 2019;39:543-551.
DOI: https://doi.org/10.1007/s40261-019-00776-7
Pizzi C, Mancini S, Angeloni L, et al. Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clin Pharmacol Ther 2009;86:527-532.
DOI: https://doi.org/10.1038/clpt.2009.121
Almuwaqqat Z, Jokhadar M, Norby FL, et al. Association of Antidepressant Medication Type With the Incidence of Cardiovascular Disease in the ARIC Study. J Am Heart Assoc 2019;8:e012503.
DOI: https://doi.org/10.1161/JAHA.119.012503
Kim JH, Song YK, Jang HY, et al. Major Adverse Cardiovascular Events in Antidepressant Users Within Patients With Ischemic Heart Diseases: A Nationwide Cohort Study. J Clin Psychopharmacol 2020;40:475-481.
DOI: https://doi.org/10.1097/JCP.0000000000001252
Park K, Kim S, Ko YJ, Park BJ. Comparison of risk of cardiovascular disease related adverse events between selective serotonin reuptake inhibitor users and serotonin norepinephrine reuptake inhibitor users in Korean adult patients with depression: retrospective cohort study. Psychiatry Res 2021;298:113744.
DOI: https://doi.org/10.1016/j.psychres.2021.113744
How to Cite
Boccatonda, A., D’Ardes, D., Guagnano, M. T., Cipollone, F., & Santilli, F. (2023). Selective serotonin reuptake inhibitors related bleeding risk: case report and review of literature. Emergency Care Journal, 19(3). https://doi.org/10.4081/ecj.2023.11349
Copyright (c) 2023 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
